(Q37816960)

23 August 2017

1 reference

title

Preclinical development of molecular-targeted agents for cancer (English)

1 reference

23 August 2017

1

0 references

Ian F. Tannock

series ordinal

4

object named as

Ian F Tannock

1 reference

23 August 2017

2

Atanasio Pandiella

1 reference

23 August 2017

3

Lillian L Siu

1 reference

PubMed ID

21135887

23 August 2017

language of work or name

English

0 references

publication date

7 December 2010

1 reference

Nature Reviews Clinical Oncology

23 August 2017

1 reference

23 August 2017

8

1 reference

23 August 2017

4

1 reference

23 August 2017

200-209

1 reference

Economics of new oncology drug development

23 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Can the pharmaceutical industry reduce attrition rates?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Translational research: are we on the right track? 2008 American Society for Clinical Investigation Presidential Address

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

The mighty mouse: genetically engineered mouse models in cancer drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Comparing solid tumors with cell lines: implications for identifying drug resistance genes in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Concomitant versus sequential chemotherapy in the treatment of early-stage and metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Drug penetration in solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Co-evolution of tumor cells and their microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Cancer stem cells in solid tumours: accumulating evidence and unresolved questions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Prospective identification of tumorigenic breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

In vivo imaging, tracking, and targeting of cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Tumour stem cells and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Identification of selective inhibitors of cancer stem cells by high-throughput screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Microregional effects of gemcitabine in HCT-116 xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Growth and chemotherapeutic response of cells in a hollow-fiber in vitro solid tumor model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

The hollow fibre model in cancer drug screening: the NCI experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Tumor models for efficacy determination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Scaling down imaging: molecular mapping of cancer in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

The use of targeted mouse models for preclinical testing of novel cancer therapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Fluorescence molecular imaging of small animal tumor models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Mouse modeling in oncologic preclinical and translational research

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Gene expression profile of metastatic human pancreatic cancer cells depends on the organ microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Cancer modeling in the modern era: progress and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Cancer as a complex genetic trait: tumor susceptibility in humans and mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Pancreatic neoplasia induced by ras expression in acinar cells of transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in ApcDelta716 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Tissue- and site-specific DNA recombination in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

DNA recombination with a heterospecific Cre homolog identified from comparison of the pac-c1 regions of P1-related phages

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Temporally-controlled site-specific mutagenesis in the basal layer of the epidermis: comparison of the recombinase activity of the tamoxifen-inducible Cre-ER(T) and Cre-ER(T2) recombinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Applications of magnetic resonance in model systems: tumor biology and physiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Examining the acute effects of cediranib (RECENTIN, AZD2171) treatment in tumor models: a dynamic contrast-enhanced MRI study using gadopentate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer a

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Latent bone metastasis in breast cancer tied to Src-dependent survival signals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Mediators of vascular remodelling co-opted for sequential steps in lung metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Genes that mediate breast cancer metastasis to the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Utilizing RNA interference to enhance cancer drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

IRF4 addiction in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Integrated functional, gene expression and genomic analysis for the identification of cancer targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Trends in the use and role of biomarkers in phase I oncology trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Discovery and validation of biomarkers that respond to treatment with brivanib alaninate, a small-molecule VEGFR-2/FGFR-1 antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

ErbB2 is essential in the prevention of dilated cardiomyopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Novel tyrosine kinase inhibitors in the treatment of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Overriding imatinib resistance with a novel ABL kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

The concept of synthetic lethality in the context of anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Hallmarks of 'BRCAness' in sporadic cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Synthetic lethality--a new direction in cancer-drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Validation of the Royal Marsden hospital prognostic index in advanced esophagogastric cancer using individual patient data from the REAL 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Opinion: Comparative biology of mouse versus human cells: modelling human cancer in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Transcription and promoter usage of the myc gene in normal somatic and spermatogenic cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

High resolution computed tomography and MRI for monitoring lung tumor growth in mice undergoing radioimmunotherapy: correlation with histology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Sonographic evaluation of orthotopic bladder tumors in mice treated with TNP-470, an angiogenic inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Radioiodinated antibody targeting of the HER-2/neu oncoprotein: effects of labeling method on cellular processing and tissue distribution

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: current status and future directions.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Do we have to change the way targeted drugs are developed?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.194

Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia

31 March 2020

1 reference

12 December 2020

Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).

1 reference

12 December 2020

The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.

1 reference

12 December 2020

Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model

1 reference

12 December 2020

Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition

1 reference

12 December 2020

The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells

1 reference

12 December 2020

Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis

1 reference

12 December 2020

Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225.

1 reference

12 December 2020

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

1 reference

12 December 2020

Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins

1 reference

12 December 2020

Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma

1 reference

12 December 2020

10.1038/NRCLINONC.2010.194

Identifiers

DOI

1 reference

23 August 2017

1 reference

PubMed ID

21135887